Breaking News, Collaborations & Alliances

Lotte Biologics and Merck Ink Biomanufacturing and Process Development Partnership

Collaboration follows the 2022 agreement for the expansion of the Syracuse bio campus plant.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lotte Biologics and Merck have signed a Letter of Intent (LOI) for a strategic partnership in biopharmaceutical manufacturing and process development. The signing ceremony was attended by key executives, including Richard Lee, CEO of Lotte Biologics, and Sebastian Arana, executive vice president of Merck. Through this agreement, the two companies plan to cooperate on the following initiatives: • Supply of essential raw materials and solutions for the development and production of biopha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters